Author

Michael Nemunaitis

Observed names: M Nemunaitis, Michael C. Nemunaitis

Observed institutions: Madigan Army Medical Center, Baylor University Medical Center, Mary Crowley Cancer Research Center, Sarah Cannon, Duke Medical Center, University of South Alabama

OpenAlex ID: A5113495737

A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors

2009 · John Nemunaitis, Alex W Tong, et al. · Molecular Therapy · 269

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

2009 · J Nemunaitis, M Nemunaitis, et al. · Cancer Gene Therapy · 154

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

2008 · Minal Barve, James Bender, et al. · Journal of Clinical Oncology · 99

p53 therapy in a patient with Li-Fraumeni syndrome

2007 · Neil Senzer, John Nemunaitis, et al. · Molecular Cancer Therapeutics · 53

Proof concept for clinical justification of network mapping for personalized cancer therapeutics

2007 · J Nemunaitis, N Senzer, et al. · Cancer Gene Therapy · 19

NF1 in Solid Tumors: The Unknown Soldier of Tumor Suppressor Genes?

2019 · Leslie L Lin, Khalil Choucair, et al. · Genetics & Molecular Medicine · 4

Primary Effusion Lymphoma Diagnosed by Pericardiocentesis

2009 · Michael C. Nemunaitis, Jeffrey M. Schussler, et al. · Baylor University Medical Center Proceedings · 4

378. Phase I Trial of Intravenous Infusion of Onyx 015 and Enbrel in Solid Tumor Patients

2006 · Gerald Edelman, Neil Senzer, et al. · Molecular Therapy · 4

Works count: 9

Citation count: 606

H-index: 5

I10-index: 5